Pharsight

1. List of Multaq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410167	SANOFI AVENTIS US	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality	Apr, 2029 (6 years from now)
US9107900	SANOFI AVENTIS US	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality	Apr, 2029 (6 years from now)
US8602215	SANOFI AVENTIS US	Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation	Jun, 2031 (8 years from now)

Market Authorisation Date: 01 July, 2009

Treatment: Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af

Dosage: TABLET;ORAL